NewAmsterdam Pharma (NASDAQ:NAMSW) Shares Down 0.4% – Here’s Why

Shares of NewAmsterdam Pharma (NASDAQ:NAMSW) were down 0.4% during trading on Wednesday. The company traded as low as $9.79 and last traded at $10.9050. Approximately 951 shares traded hands during trading, a decline of 54% from the average daily volume of 2,089 shares. The stock had previously closed at $10.95.

NewAmsterdam Pharma Stock Down 18.1%

The firm’s fifty day simple moving average is $13.81 and its 200 day simple moving average is $18.90.

Institutional Investors Weigh In On NewAmsterdam Pharma

An institutional investor recently bought a new position in NewAmsterdam Pharma stock. Headlands Technologies LLC acquired a new position in NewAmsterdam Pharma (NASDAQ:NAMSW) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 72,335 shares of the company’s stock, valued at approximately $1,546,000.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for dyslipidemia and other conditions associated with cardiovascular disease. Its lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve patients’ lipid profiles.

The company is evaluating obicetrapib in late-stage clinical trials for patients whose cholesterol remains inadequately controlled despite existing treatment.